Indication
Metastatic Tumors
2 clinical trials
2 products
2 drugs
Clinical trial
A Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Initial Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Patients With Locally Advanced/Metastatic Solid Tumors or LymphomaStatus: Recruiting, Estimated PCD: 2023-09-01
Product
HLX301Clinical trial
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10)Status: Active (not recruiting), Estimated PCD: 2029-01-01
Drug
CisplatinDrug
PD-1 antibodyProduct
Hormones